Rifapentine plus Isoniazid
ApprovedSmall molecule
Rifapentine plus Isoniazid is one of 65 small molecule programs targeting Kidney Disease. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Rifadin
SanofiPhase 3
Ziagen
GSKPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Ethambutol Hydrochloride
PfizerPhase 3
Rifapentine plus Isoniazid
HHuashan Hospital
Approved
Pyridoxine Hydrochloride
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Isoniazid for 9 Months
NNational Taiwan University Hospital
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Kanamycin
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
Tivicay
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rifapentine plus Isoniazid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHuashan Hospital